EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The potential of artificial intelligence in clinical trials

Rahul Aggarwal iD, Deepak L Bhatt iD

European Journal of Clinical Investigation · 2026-03 · 56 (3)

DOI: 10.1111/eci.70182 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 27.02.2026. Verfasst von Rahul Aggarwal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials are an important part of evidence generation in medicine but remain burdened by escalating costs, inefficiencies and manual processes. Artificial intelligence (AI) has emerged as a promising approach to address these limitations by improving efficiency across the trial lifecycle.

Methods

In this review, we examine emerging applications of AI across the clinical trial lifecycle. We highlight key examples demonstrating feasibility and potential impact.

Results

AI‐based approaches show promise in optimizing trial design, improving recruitment, streamlining conduct and enhancing data interpretation. Despite the potential of AI in trials, challenges persist, including data quality, regulatory and privacy concerns, as well as infrastructure issues. Ethical use will require strong governance frameworks emphasizing transparency and human oversight. The success of these technologies will depend on their continuous validation and monitoring of these technologies.

Conclusions

With appropriate validation, monitoring and governance, AI could enable a more efficient, cost‐saving and effective clinical trial landscape that accelerates discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceClinical Trials as TopicHumansResearch DesignPatient SelectionData Accuracy

Stichwörter der Autor:innen

artificial intelligenceclinical trialsdigital technology

Autor:innen und Institutionen

  • Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Massachussetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Rahul Aggarwal, Deepak L Bhatt

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Aggarwal, R., & Bhatt, D. L. (2026). The potential of artificial intelligence in clinical trials. European Journal of Clinical Investigation, 56(3). https://doi.org/10.1111/eci.70182

Vancouver

Aggarwal R, Bhatt DL. The potential of artificial intelligence in clinical trials. European Journal of Clinical Investigation. 2026;56(3). doi:10.1111/eci.70182

BibTeX
@article{Aggarwal2026,
  author = {Aggarwal, Rahul and Bhatt, Deepak L},
  title = {The potential of artificial intelligence in clinical trials},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {3},
  doi = {10.1111/eci.70182}
}
Kostenlos starten →